Leukemia Cancer Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

The global leukemia cancer market is anticipated to grow at a considerable CAGR of 5.1% during the forecast period. Increasing investments in the healthcare sector and the rising development of new drugs and therapeutics will drive the market in the forecast period. According to WHO, globally leukemia cancer is considered to be the most common blood cancer. Thus, to treat and cure rising incidences of cancer across the globe, drug manufacturers and market players are conducting several R&D activities. For instance, in March 2022, Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on R&D for novel cancer therapeutics, today announced that the first patient has been dosed in the Phase 1/2 study of DSP-5336, an inhibitor of melanin binding to mixed-lineage leukemia (MLL) protein, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL).

A full report of Leukemia Cancer Market is available at: https://www.omrglobal.com/industry-reports/leukemia-cancer-market

In September 2021, Intas Pharmaceuticals Ltd announced the launch of Azadine-O, an oral Azacitidine therapy for Acute Myeloid Leukemia (a type of blood cancer), a first for the Indian market. Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It can improve survival by almost 10 months and bridge a long-pending unmet need in cancer therapy.

Further, in December 2020, Jazz Pharmaceuticals plc announced that the company has initiated the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking marketing approval for JZP-458 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/leukemia-cancer-market

Market Coverage

The market number available for - 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
o By Type

o By Diagnose & Monitor

o By Treatment

Regions Covered-
o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- including Bristol-Myers Squibb, Celgene Corp., Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., and others.

Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Leukemia Cancer Market Report Segment

By Type

Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Acute Lymphoblastic Leukemia (ALL)
Chronic Lymphocytic Leukemia (CLL)

By Diagnose & Monitor

Blood Test
Bone Marrow Test
Imaging Test
Lymph Node Biopsy
Lumbar Puncture
Urine Test

By Treatment

Chemotherapy
Radiation Therapy
Targeted Therapy
Biological Therapy
Stem Cell Therapy

Leukemia Cancer Market- Segment by Region

North America

United States
Canada

Europe

Germany
United Kingdom
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

Actinium Pharmaceuticals Inc.
Biogen Idec Inc.
Bristol-Myers Squibb
Celgene Corp. (Bristol-Myers Squibb)
Daiichi Sankyo Co., Ltd.
Eisai Co. Ltd.
Epizyme Inc.
Erytech Pharma S.A.
Hoffmann-La Roche Ltd.
Genmab A/S
Glaxosmithkline Plc
Novartis International AG
Pfizer Inc.
Sanofi

Reasons to Buying From us -

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.